Asuragen to Present at Upcoming Piper Jaffray Healthcare Conference
Asuragen President and Chief Executive Officer, Matthew McManus M.D., Ph.D., will present at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 10:50 a.m. Eastern Time in New York.
Introducing the first and only FDA cleared BCR-ABL1 assay
We are pleased to announce that we have received FDA clearance through the de novo 510(k) process for our QuantideX qPCR BCR-ABL IS Kit for monitoring molecular response in Chronic Myeloid Leukemia patients.
The American Society of Hematology (ASH) Annual Meeting & Exposition is a comprehensive hematology meeting that provides educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Visit us at booth #2561.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.